Business Wire

NY-PYRAMID-ANALYTICS

21.3.2023 16:26:47 CET | Business Wire | Press release

Share
Pyramid Analytics revolutionizes “Last Mile” analytics with Tabulate and Solve

Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today that it is showcasing its latest additions to its award-winning Decision Intelligence Platform—Tabulate, a powerful new business modeling module; and Solve, a decision modeling and optimization plug-in for Tabulate—at the Gartner Data & Analytics Summit in Orlando, Florida, and at SAPinsider Vegas 2023 in Las Vegas, Nevada. Launched in October 2022, Tabulate lets business users model business processes with data in a governed, web-based experience while Solve allows business users to easily build and deploy advanced prescriptive and optimization models to guide data-driven decision-making on live data.

Solving the last mile of analytics

In an independent research survey of data workers commissioned by Pyramid in 2022, over 50 percent of respondents who already use BI tools said they exported their analytical data to Excel 50 percent of the time or more to build business models to drive the last mile decision frameworks they need in their jobs. Pyramid added Tabulate and the Solve plug-in to address this “last mile” challenge and complete its “Data Factory for Decisions” paradigm: an end-to-end data fabric, analytics, and AI-driven assembly line that takes data from conception to decision point through a no-code, frictionless experience for business users.

Tabulate, a browser-based virtual spreadsheet that functionally matches desktop spreadsheet tools, allows business users to combine data from multiple data sources with their own business models and logic that reflects business processes that are not inherently captured in the data itself. The data is read live and directly from sources, without ingestion or duplication, vastly increasing time to insights while eliminating governance and security issues.

Solve, a plug-in for Tabulate, enables decision modeling by generating prescriptive and optimization models to drive real what-if analysis, simulations, and actual decision generation. The use cases are limitless, from supply-chain optimization to product price calculations and personnel scheduling.

Best of all, Tabulate and Solve, like all other elements in the Pyramid analytic catalog, can be deployed and consumed by other users on the Pyramid platform without ever having to take custody of the underlying models or spreadsheet content directly.

Key points:

  • For years, there has been an elusive “Last Mile” of data analytics, which hinders business users from generating answers to the question: “How do we make it happen?” The launch of Tabulate and Solve means the Pyramid Platform has bridged that gap—supporting the data journey from creation to the end-user decision point.
  • Tabulate is designed for business modeling by business users of all levels through a very familiar and comprehensive spreadsheet experience, complete with the 500+ functions found in other well-known spreadsheet tools.
  • Tabulate enables business users to build and deploy business models using live data, no matter where it is.
  • The Solve plug-in allows business users to build optimization models with complex logic waterfalls, conditions, and decision points. These can drive prescriptive analytics, optimization logic, what-if scenarios, and simulations.
  • Tabulate and Solve are the latest innovation in Pyramid’s ongoing mission to enable business users to absorb data and enrich it with models and values, embellish it through logic, and gain insights through visualization and interrogation.

In the upcoming Pyramid 2023 release, users will be able to generate spreadsheet formulas in Tabulate using GPT-based natural language from the newly announced OpenAI integration.

Click here to schedule a demo of the Pyramid Decision Intelligence Platform.

Taking business intelligence to the next level

Today’s data-driven businesses are making faster, more accurate decisions based on facts rather than perception. But businesses need a platform that fully leverages all their data to become truly data-driven. Many organizations have discovered that their current business intelligence platforms are incomplete and not fit for purpose—focusing on data visualization rather than providing fast, accurate answers to actual business questions. This leaves them stuck in the past, making slow decisions, no decisions, or worse, bad decisions.

The Pyramid Decision Intelligence Platform changes that. It empowers people with AI augmentation, automation, and collaborative insights that simplify and guide the use of data in decision-making. It combines governed self-service analytics with AI and brings data prep, business analytics, and data science together into one frictionless platform.

Quotes:

Avi Perez, CTO and Co-Founder, Pyramid Analytics: “Tabulate and Solve are an exciting and mechanically crucial element in the data factory—a concept that has been part of the original Pyramid roadmap for over a decade. One of the most significant data challenges businesses face is the risks associated with moving data between standalone platforms or exporting to traditional spreadsheets stored on local machines. Tabulate removes the risks of this with governed direct connectivity, with data able to be utilized, deployed, and analyzed from any platform. Solve brings elusive prescriptive analytics to self-service ABI platforms. Both expansions help deliver true decision intelligence using real-time data.”

Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “When we originally conceived the idea for the Pyramid platform, we set out to bring complex and sophisticated decision-making solutions to the general business user. Pyramid wants everyone, from CEOs to frontline workers, to gain valuable insights from data and make informed business decisions. The Tabulate and Solve expansion is the next step in the journey of making that dream a concrete reality. They combine sophistication, adaptability, functionality, and familiarity to create an easy-to-use, valuable tool for business users.”

About Pyramid Analytics

Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with AI-augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005715/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye